CervoMed Inc
CRVO7.600USD
-0.300-3.80%
收盤 12/19, 16:00（美東）報價延遲15分鐘
70.32M總市值
虧損本益比TTM
關於 CervoMed Inc 公司
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
CervoMed Inc簡介
公司代碼CRVO
公司名稱CervoMed Inc
上市日期Nov 09, 2016
CEOAlam (John J)
員工數量15
證券類型Ordinary Share
年結日Nov 09
公司地址20 Park Plaza, Suite 424
城市BOSTON
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編02116
電話16177444400
網址https://cervomed.com/
公司代碼CRVO
上市日期Nov 09, 2016
CEOAlam (John J)
CervoMed Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.29K
+3.08%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. David Quigley
Mr. David Quigley
Director
Director
--
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Dr. Claudia Ordonez, M.D.
Dr. Claudia Ordonez, M.D.
Senior Vice President - Medical Science
Senior Vice President - Medical Science
--
--
Dr. Marco Verwijs, Ph.D.
Dr. Marco Verwijs, Ph.D.
Executive Vice President - Technical Operations
Executive Vice President - Technical Operations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
753.29K
+3.08%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Mr. David Quigley
Mr. David Quigley
Director
Director
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
8.14%
Alam (John J)
8.14%
Morgan Stanley & Co. LLC
4.43%
其他
58.53%
持股股東
持股股東
佔比
Boger (Joshua S)
11.43%
AWM Investment Company, Inc.
9.33%
Gregoire (Sylvie L.)
8.14%
Alam (John J)
8.14%
Morgan Stanley & Co. LLC
4.43%
其他
58.53%
股東類型
持股股東
佔比
Individual Investor
32.17%
Investment Advisor/Hedge Fund
11.21%
Investment Advisor
6.37%
Research Firm
4.45%
Hedge Fund
1.42%
其他
44.38%
機構持股
更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
123
2.18M
45.61%
--
2025Q3
124
2.18M
46.47%
-3.07K
2025Q2
112
2.18M
47.13%
-111.10K
2025Q1
106
2.29M
39.48%
-1.15M
2024Q4
98
1.50M
41.86%
-2.03M
2024Q3
82
3.52M
43.30%
+50.30K
2024Q2
68
3.46M
36.20%
+585.47K
2024Q1
43
2.52M
7.33%
+2.06M
2023Q4
40
327.50K
7.25%
-36.20K
2023Q3
40
363.70K
2.81%
+241.80K
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Boger (Joshua S)
1.06M
11.43%
--
--
Apr 24, 2025
AWM Investment Company, Inc.
863.20K
9.33%
--
--
Jun 30, 2025
Gregoire (Sylvie L.)
730.79K
7.9%
-1.25K
-0.17%
Apr 24, 2025
Alam (John J)
730.79K
7.9%
+1.25K
+0.17%
Apr 24, 2025
Morgan Stanley & Co. LLC
371.23K
4.01%
+240.63K
+184.25%
Jun 30, 2025
Zavrl (Frank E.)
353.01K
3.82%
--
--
Apr 24, 2025
The Vanguard Group, Inc.
340.02K
3.67%
-38.64K
-10.21%
Jun 30, 2025
Millennium Management LLC
76.08K
0.82%
+76.08K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
54.26K
0.59%
-62.23K
-53.42%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
97.58K
1.05%
-223.90K
-69.65%
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 Growth ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
ProShares UltraPro Russell2000
佔比0%
iShares Health Innovation Active ETF
佔比0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
公告日期
類型
比率
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
常見問題
CervoMed Inc的前五大股東是誰？
CervoMed Inc的前五大股東如下：
Boger (Joshua S)持有股份：1.06M佔總股份比例：11.43%。
AWM Investment Company, Inc.持有股份：863.20K佔總股份比例：9.33%。
Gregoire (Sylvie L.)持有股份：730.79K佔總股份比例：7.90%。
Alam (John J)持有股份：730.79K佔總股份比例：7.90%。
Morgan Stanley & Co. LLC持有股份：371.23K佔總股份比例：4.01%。
Boger (Joshua S)持有股份：1.06M佔總股份比例：11.43%。
AWM Investment Company, Inc.持有股份：863.20K佔總股份比例：9.33%。
Gregoire (Sylvie L.)持有股份：730.79K佔總股份比例：7.90%。
Alam (John J)持有股份：730.79K佔總股份比例：7.90%。
Morgan Stanley & Co. LLC持有股份：371.23K佔總股份比例：4.01%。
CervoMed Inc的前三大股東類型是什麼？
CervoMed Inc 的前三大股東類型分別是：
Boger (Joshua S)
AWM Investment Company, Inc.
Gregoire (Sylvie L.)
Boger (Joshua S)
AWM Investment Company, Inc.
Gregoire (Sylvie L.)
有多少機構持有CervoMed Inc(CRVO)的股份？
截至2025Q4，共有123家機構持有CervoMed Inc的股份，合計持有的股份價值約為2.18M，占公司總股份的45.61% 。與2025Q3相比，機構持股有所增加，增幅為-0.85%。
哪個業務部門對CervoMed Inc的收入貢獻最大？
在--，--業務部門對CervoMed Inc的收入貢獻最大，創收--，占總收入的--% 。
